山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (6): 101-105.doi: 10.6040/j.issn.1673-3770.0.2022.345
• 论著 • 上一篇
王露萍1,寇芳柠2,王皓3,张灿伟4,王艳玲1,尤冉1,吴伟珍1
WANG Luping1, KOU Fangning2, WANG Hao3, ZHANG Canwei4, WANG Yanling1, YOU Ran1, WU Weizhen1
摘要: 目的 探讨视网膜下高反射物质(SHRM)对抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性(nAMD)患者视力预后的影响。 方法 回顾性分析确诊为nAMD的50例患者(50眼)。将患者分为2组,视力提高组共27眼,视力未提高组共23眼,分析SHRM是否影响患者视力预后。通过对比基线和终点有无SHRM,患者基线和终点视力有无差异,评价SHRM在治疗前后对患者视力的影响。 结果 两组患者性别、年龄、基线最佳矫正视力(BCVA)、基线中心凹厚度(CMT)、基线SHRM宽度和高度、注射次数差异均无统计学意义。治疗12个月后,视力提高组患者CMT(P=0.027)、SHRM宽度(P=0.036)和高度(P=0.027)均小于视力未提高组。此外,存在基线SHRM的nAMD患者,基线BCVA低于无基线SHRM的患者(P=0.022);无基线/终点SHRM的患者,终点BCVA明显优于存在基线/终点SHRM的患者(P=0.015,P=0.008)。 结论 终点视力较基线视力提高的患者,SHRM宽度和高度较小;存在基线或终点SHRM的患者视力预后较差。SHRM可能作为nAMD患者的光学相干断层扫描生物标志物,协助眼科医生预测患者视力预后。
中图分类号:
[1] Song PG, Du YH, Chan KY, et al. The national and subnational prevalence and burden of age-related macular degeneration in China[J]. J Glob Health, 2017, 7(2): 020703. doi:10.7189/jogh.07.020703. [2] 赵露, 谢国丽, 王艳玲. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者眼血流动力学的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 101-104. doi:10.6040/j.issn.1673-3770.0.2015.481. ZHAO Lu, XIE Guoli, WANG Yanling. Changes of ocular hemodynamics after intravitreal ranibizumab injection in patients with wet age-related macular degeneration[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2016, 30(4): 101-104. doi:10.6040/j.issn.1673-3770.0.2015.481. [3] Lanzetta P, Cruess AF, Cohen SY, et al. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies[J]. Acta Ophthalmol, 2018, 96(8): e911-e918. doi:10.1111/aos.13751. [4] Willoughby AS, Ying GS, Toth CA, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials[J]. Ophthalmology, 2015, 122(9): 1846-1853.e5. doi:10.1016/j.ophtha.2015.05.042. [5] Shah VP, Shah SA, Mrejen S, et al. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration[J]. Retina, 2014, 34(7): 1281-1288. doi:10.1097/IAE.0000000000000166. [6] Alex D, Giridhar A, Gopalakrishnan M, et al. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: a case control study[J]. Indian J Ophthalmol, 2021, 69(7): 1862-1866. doi:10.4103/ijo.IJO_3156_20. [7] 石佳, 孙大卫. 雷珠单抗治疗新生血管性年龄相关性黄斑变性方案的临床推荐[J]. 国际眼科纵览, 2019, 43(2): 111-117. doi:10.3760/cma.j.issn.1673-5803.2019.02.008. [8] Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration(nAMD): recommendations for management and service provision in the UK hospital eye service[J]. Eye(Lond), 2019, 33(1): 1-21. doi:10.1038/s41433-018-0300-3. [9] Sarkar A, Junnuthula V, Dyawanapelly S. Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration(nAMD)[J]. Int J Mol Sci, 2021, 22(19): 10594. doi:10.3390/ijms221910594. [10] Patel P, Sheth V. New and innovative treatments for neovascular age-related macular degeneration(nAMD)[J]. J Clin Med, 2021, 10(11): 2436. doi:10.3390/jcm10112436. [11] 余岚, 陈长征, 易佐慧子, 等. 玻璃体腔注射康柏西普治疗渗出型老年性黄斑变性的疗效观察[J]. 中华眼底病杂志, 2015, 31(3): 256-259. doi:10.3760/cma.j.issn.1005-1015.2015.03.011. [12] 中华医学会眼科学分会眼底病学组. 中国老年性黄斑变性临床诊断治疗路径[J]. 中华眼底病杂志, 2013, 29(4): 343-355. doi:10.3760/cma.j.issn.1005-1015.2013.04.002. [13] 张陶然, 王薇, 李明铭, 等. IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 68-71. doi:10.6040/j.issn.1673-3770.0.2021.059. ZHANG Taoran, WANG Wei, LI Mingming, et al. Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 68-71.doi:10.6040/j.issn.1673-3770.0.2021.059. [14] Finger RP, Daien V, Eldem BM, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration-a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems[J]. BMC Ophthalmol, 2020, 20(1): 294. doi:10.1186/s12886-020-01554-2. [15] Yerramothu P. New therapies of neovascular AMD-beyond anti-VEGFs[J]. Vision(Basel), 2018, 2(3): E31. doi:10.3390/vision2030031. [16] Wang L, Zhang C, Hua R. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis[J]. Drug Des Devel Ther, 2018,29(12):3625-3633.doi: 10.2147/DDDT.S176021. [17] Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials[J]. Ophthalmology, 2016, 123(7): 1521-1529. doi:10.1016/j.ophtha.2016.03.037. [18] Alex D, Giridhar A, Gopalakrishnan M, et al. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: a case control study[J]. Indian J Ophthalmol, 2021, 69(7): 1862-1866. doi:10.4103/ijo.ijo_3156_20. [19] Alex D, Giridhar A, Gopalakrishnan M, et al. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: a case control study[J]. Indian J Ophthalmol, 2021, 69(7):1862-1866. doi: 10.4103/ijo.IJO_3156_20. [20] Roberts PK, Schranz M, Motschi A, et al. Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration[J]. Sci Rep, 2022, 12(1): 88. doi:10.1038/s41598-021-03716-8. [21] Keane PA, Liakopoulos S, Chang KT, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration[J]. Ophthalmology, 2008, 115(12): 2206-2214. doi:10.1016/j.ophtha.2008.08.016. [22] Cheung CMG, Grewal DS, Teo KYC, et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration[J]. Ophthalmol Retina, 2019, 3(12): 1045-1055. doi:10.1016/j.oret.2019.06.002. [23] Fayed AE, Baddar D, Estawro RG, et al. Masking of macular neovascular membranes by subretinal hyperreflective material on optical coherence tomography angiography[J]. Eur J Ophthalmol, 2022, 32(6): 3547-3555. doi:10.1177/11206721221085396. [24] Ehlers JP, Zahid R, Kaiser PK, et al. Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and subretinal pigment epithelium disease in neovascular age-related macular degeneration[J]. Ophthalmol Retina, 2021, 5(12): 1204-1213. doi:10.1016/j.oret.2021.02.012. [25] Ehlers JP, Patel N, Kaiser PK, et al. The association of fluid volatility with subretinal hyperreflective material and ellipsoid zone integrity in neovascular AMD[J]. Invest Ophthalmol Vis Sci, 2022, 63(6): 17. doi:10.1167/iovs.63.6.17. [26] Fang M, Chanwimol K, Maram J, et al. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy[J]. Br J Ophthalmol, 2021. doi:10.1136/bjophthalmol-2021-319602. |
[1] | 刘志高,王淑雅,韩旭光,王玉,李志伟,马爱华,赵博军. 增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 99-103. |
[2] | 谢丽,魏伟. 糖尿病性黄斑水肿的治疗进展[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 81-85. |
|